Table of Content

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What’s New in This Update?
Methodology
Information Sources
Geographic Breakdown

Chapter 2 Summary and Highlights
Market Overview

Chapter 3 Market Overview
Introduction
Is There a Problem with Human Blood?
Emerging Needs for Artificial Blood
Artificial Blood Will Be Useful in Dealing with the Risks of Infection
Artificial Blood Will Help to Decrease the Load on the Donor Blood Supply
Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System
Hurdles in the Development of Artificial Blood Products
Ideal Characteristics of Artificial Blood
Artificial Blood Over Human Blood
Applications
Surgeries
Emergency Resuscitation
For Short-term Use
Where More Effective Than Human Blood
Rejections Due to Religious Beliefs
Challenges in Artificial Blood Development

Chapter 4 Market Dynamics
Drivers
Increasing Demand for Blood Transfusions
Risks and Challenges Associated with Blood Transfusions
Shortage of Blood Supply
Barriers
Low Rate of Product Approvals
Product Acceptance
Product Pricing
Opportunities
Impact of COVID-19

Chapter 5 Artificial Blood by Source
Introduction
Artificial Blood Developed from Human Blood
Artificial Blood Developed from Animal Blood
Artificial Blood Developed Using Recombinant Technology
Surface Modified Hemoglobin
Cross-Linked Hemoglobin
Polymerized Hemoglobin
Encapsulation
Genetically Engineered Recombinant Hemoglobin
Natural Hemoglobin

Chapter 6 Artificial Blood by Type
Introduction
Perfluorocarbon Emulsions
General Characteristics of Perfluorocarbons
Emulsion Selection
Historical Developments of Perfluorocarbon Emulsions
First Generation of PFCs
Second Generation of PFCs
Third Generation of PFCs
Hemoglobin-based Oxygen Carriers
General Characteristics of HBOCs
Historical Events: Hemoglobin Solutions

Chapter 7 Market Estimation
Introduction
Potential Market for Artificial Blood
Artificial Blood Market, by Source
Blood (Animal/Human)
Synthetic Polymers
Artificial Blood Market, by Type
Hemoglobin-based Oxygen Carriers
Perfluorocarbon-based Products
Artificial Blood Market, by Region
North America
Europe
Emerging Markets

Chapter 8 Emerging Technologies and Developments
Overview
Emerging Technologies
Nanocapsule Technology
Stem Cells
Other Ongoing Research for Blood Substitutes

Chapter 9 Product Analysis
Introduction
Product Safety
Product Effectiveness
Product Cost
Legal Implications
Product Analysis of Some of the Products Under Development
Hemopure
HemO2life
HemoTech
NanO2 (DDFPe)
Sanguinate
Vidaphor
Clinical Trials
Product Description of Some of the Products in Preclinical and Early Phase I Stage
ErythroMer
Hemoglobin vesicles
OxyVita
OxyBridge

Chapter 10 Patent Analysis
Introduction
FDA Regulation
FDA Good Manufacturing Practices and Reporting
Patent Analysis

Chapter 11 Competitive Intelligence
Strategic Developments
Competitive Analysis

Chapter 12 Company Profiles
AURUM BIOSCIENCES
ERYPHARM
HEMOGLOBIN OXYGEN THERAPEUTICS LLC.
HEMARINA
KALOCYTE INC.
NANO SANGUIS S.A
NUVOX PHARMA LLC.
PROLONG PHARMACEUTICALS, LLC
RED C BIOTECH
VIRTECH BIO



List of Figures


Summary Figure : Global Market for Artificial Blood, 2020-2028
Figure 1 : The Blood Continuum
Figure 2 : Medical Use of Human Red Blood Cells in the U.S., 2019
Figure 3 : Estimated Number of New Cancer Cases from 2020 to 2040
Figure 4 : Discards of Blood Donations, by Reason, 2018
Figure 5 : Artificial Blood Manufactured from Different Sources
Figure 6 : History of HBOCs Developed Using Recombinant Technology
Figure 7 : Classification of Modified Hemoglobin Solution Based on Methods
Figure 8 : Classification of Different Types of Oxygen Carriers
Figure 9 : Generations of Perfluorocarbon Emulsions
Figure 10 : Advantages and Disadvantages of PFC Emulsions
Figure 11 : Evolution of HBOCs
Figure 12 : Advantages and Disadvantages of HBOCs
Figure 13 : Global Potential Market for Artificial Blood, by Application, 2028
Figure 14 : Biosynthetic RBC vs Artificial Blood Substitutes
Figure 15 : Artificial Blood: Parameters for Product Analysis
Figure 16 : Hemopure: Product Analysis
Figure 17 : HemO2life: Product Analysis
Figure 18 : NanO2 (DDFPe): Product Analysis
Figure 19 : Sanguinate: Product Analysis
Figure 20 : Current Competition in the Global Artificial Blood Market

List of Tables


Summary Table : Global Market for Artificial Blood, Through 2028
Table 1 : Historical Events Related to Blood Transfusion, 1628-2022
Table 2 : Potential Benefits and Application Areas of Artificial Blood
Table 3 : Average Number of Blood Units Required During Particular Medical Conditions
Table 4 : The Challenges Associated with the Development of Artificial Blood
Table 5 : Common Challenges to the Blood Transfusion Continuum in LMICs.
Table 6 : Sources of Hemoglobin Molecules Used to Prepare Free Hemoglobin Solutions
Table 7 : Pros and Cons of Artificial Blood Developed from Human Blood
Table 8 : Pros and Cons of Artificial Blood Developed from Animal Blood
Table 9 : Pros and Cons of Artificial Blood Developed from Recombinant Blood
Table 10 : Summary of Acellular Hb-Based Oxygen Carriers
Table 11 : Examples of Hemoglobin-based Oxygen Carrier Products and Approval Status
Table 12 : Potential Clinical Applications of Oxygen Carriers
Table 13 : Composition of PFC Emulsion-Based Artificial Blood Products
Table 14 : First Generation Perfluorocarbon Emulsions Used in Medicine and Biology
Table 15 : Comparative Study of Second-Generation PFCs
Table 16 : PFC Emulsion Products and Current Status
Table 17 : Comparative Study Between RBCs and HBOCs
Table 18 : HBOC Solutions Transfusion: Side Effects and Possible Causes
Table 19 : Examples of HBOC Products Developed, by Various Companies
Table 20 : Global Market for Artificial Blood, Through 2028
Table 21 : Current Cell Sources and Strategies for Ex-vivo RBC Generation
Table 22 : List of Discontinued Blood Substitutes
Table 23 : Hemopure: Raw Material and Method Overview
Table 24 : Hemopure: Product Characteristics
Table 25 : Hemopure: Advantages and Disadvantages
Table 26 : Summary of Clinical Trials of Hemopure (HBOC-201), 2023
Table 27 : HemO2life: Raw Material and Method
Table 28 : HemO2life: Advantages and Disadvantages
Table 29 : HemO2life: Product
Table 30 : Ex vivo, In vivo and Clinical Studies involving HemO2life (M101) Use
Table 31 : Hemotech: Raw Material and Method Overview
Table 32 : HemoTech: Advantages and Disadvantages
Table 33 : NanO2 (DDFPe): Raw Material and Method Overview
Table 34 : NanO2 (DDFPe): Advantages and Disadvantages
Table 35 : NanO2 (DDFPe): Clinical Trials, 2023
Table 36 : Sanguinate: Raw Material and Method Overview
Table 37 : Sanguinate: Advantages and Disadvantages
Table 38 : Sanguinate: Clinical Trials, 2023
Table 39 : Vidaphor: Raw Material and Method Overview
Table 40 : Vidaphor: Advantages and Disadvantages
Table 41 : Vidaphor: Clinical Trials, 2023